Durata Therapeutics (NASDAQ: DRTX) today announced data from an in vitro study and surveillance results of its lead product candidate, dalbavancin, currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The data, presented at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), demonstrate the potency of dalbavancin against numerous significant bacterial isolates in the United States and Europe.
Comparative In Vitro Activity of Dalbavancin (DAL) and Other Gram-Positive Agents Against a Recent Collection of European Bacterial Isolates (Simenauer, et al). Session Number 010, Presentation Number: C2-134
Study conclusions: On a MIC 90 (Minimum Inhibitory Concentration required to inhibit the growth of 90% of organisms) basis, dalbavancin was more potent than vancomycin, linezolid or daptomycin for every organism group studied. These findings indicate that dalbavancin continues to have potent activity against target pathogens isolated in Europe. (These in vitro data were generated by Dr. Dan Sahm and his team at Eurofins Medinet, Chantilly, Va.)
Update of Dalbavancin (DAL) Activity in the USA: Report from the SENTRY Program (2011). (Jones, et al). Session Number: 010, Presentation Number: C2-138Study conclusions: Year 2011 SENTRY Program surveillance results for dalbavancin (DAL) document sustained potent activity against Staphylococcus aureus (SA), coagulase-negative staphylococci (CoNS), beta-hemolytic streptococci (βHS), viridans gr. streptococci (VGS) and vancomycin-susceptible (VANC-S) enterococci, that averaged four-to 32-fold greater than vancomycin, daptomycin or linezolid. Further development of dalbavancin appears warranted by these in vitro potency criteria. (These in vitro data were generated from the laboratories of Dr. Ron Jones and his coauthors at the Jones Microbiology Institute Laboratories in North Liberty, Iowa.) “These results add to the growing body of evidence that dalbavancin is a highly potent agent against the Gram-positive bacteria associated with ABSSSI and many other infections of global concern,” said Durata Chief Medical Officer Michael Dunne, M.D. “We plan to use these data and clinical trial results to support our New Drug Application with the U.S. Food and Drug Administration for dalbavancin for the treatment of ABSSSI, which we continue to anticipate submitting in the first half of 2013.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV